Bioventus Historical Income Statement

BVS Stock

USD 11.71 0.20 1.74%

Historical analysis of Bioventus income statement accounts such as Interest Expense of 42.7 M, Total Revenue of 386.8 M or Gross Profit of 267.5 M can show how well Bioventus performed in making a profits. Evaluating Bioventus income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Bioventus's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Bioventus latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Bioventus is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bioventus. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For more information on how to buy Bioventus Stock please use our How to Invest in Bioventus guide.

About Bioventus Income Statement Analysis

Bioventus Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Bioventus shareholders. The income statement also shows Bioventus investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Bioventus Income Statement Chart

At this time, Bioventus' Interest Expense is comparatively stable compared to the past year. Research Development is likely to gain to about 15.1 M in 2024, whereas Total Revenue is likely to drop slightly above 386.8 M in 2024.

Total Revenue Gross Profit Other Operating Expenses Operating Income Research Development Net Income Applicable To Common Shares

Total Revenue

Total revenue comprises all receipts Bioventus generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Bioventus minus its cost of goods sold. It is profit before Bioventus operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Bioventus. It is also known as Bioventus overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Operating Income

Operating Income is the amount of profit realized from Bioventus operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Bioventus is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Net Income Applicable To Common Shares

The net income that remains after preferred dividends have been deducted, available to common shareholders.

Most accounts from Bioventus' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Bioventus current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bioventus. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For more information on how to buy Bioventus Stock please use our How to Invest in Bioventus guide.At this time, Bioventus' Interest Expense is comparatively stable compared to the past year. Research Development is likely to gain to about 15.1 M in 2024, whereas Total Revenue is likely to drop slightly above 386.8 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	1.1M	25.8M	40.7M	42.7M
Depreciation And Amortization	38.7M	61.4M	57.4M	40.7M

Interest Expense Depreciation And Amortization

Bioventus income statement Correlations

	Depreciation And Amortization	Interest Expense	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Discontinued Operations	Minority Interest	Tax Provision	Net Interest Income	Selling General Administrative	Net Income From Continuing Ops	Reconciled Depreciation	Selling And Marketing Expenses	Non Recurring	Non Operating Income Net Other
Depreciation And Amortization		0.62	0.93	0.86	0.97	-0.63	-0.83	0.76	-0.74	0.98	0.96	-0.85	-0.73	-0.86	-0.71	0.68	0.83	-0.88	-0.54	0.96	-0.88	0.95	0.91	-0.42	0.6
Interest Expense	0.62		0.57	0.53	0.62	-0.72	-0.58	0.16	-0.5	0.59	0.63	-0.6	-0.84	-0.76	-0.2	0.4	0.87	-0.54	-0.95	0.6	-0.83	0.72	0.47	-0.81	0.8
Total Revenue	0.93	0.57		0.99	0.97	-0.43	-0.64	0.66	-0.53	0.96	0.97	-0.66	-0.64	-0.69	-0.59	0.8	0.7	-0.76	-0.42	0.9	-0.77	0.86	0.87	-0.41	0.57
Gross Profit	0.86	0.53	0.99		0.92	-0.31	-0.52	0.6	-0.41	0.9	0.92	-0.55	-0.59	-0.59	-0.53	0.8	0.62	-0.68	-0.35	0.83	-0.69	0.76	0.82	-0.38	0.5
Other Operating Expenses	0.97	0.62	0.97	0.92		-0.59	-0.76	0.69	-0.67	1.0	1.0	-0.76	-0.68	-0.79	-0.61	0.74	0.79	-0.81	-0.53	0.95	-0.85	0.95	0.89	-0.44	0.66
Operating Income	-0.63	-0.72	-0.43	-0.31	-0.59		0.77	-0.44	0.74	-0.6	-0.58	0.72	0.76	0.84	0.25	-0.33	-0.85	0.58	0.85	-0.7	0.85	-0.77	-0.59	0.78	-0.81
Ebit	-0.83	-0.58	-0.64	-0.52	-0.76	0.77		-0.78	0.99	-0.78	-0.74	0.99	0.6	0.96	0.8	-0.45	-0.9	0.95	0.59	-0.89	0.91	-0.87	-0.85	0.44	-0.46
Research Development	0.76	0.16	0.66	0.6	0.69	-0.44	-0.78		-0.74	0.72	0.67	-0.78	-0.45	-0.67	-0.82	0.61	0.55	-0.83	-0.1	0.81	-0.62	0.65	0.89	-0.16	0.12
Ebitda	-0.74	-0.5	-0.53	-0.41	-0.67	0.74	0.99	-0.74		-0.7	-0.65	0.97	0.5	0.92	0.8	-0.36	-0.84	0.92	0.53	-0.82	0.85	-0.81	-0.79	0.37	-0.38
Cost Of Revenue	0.98	0.59	0.96	0.9	1.0	-0.6	-0.78	0.72	-0.7		0.99	-0.79	-0.67	-0.81	-0.65	0.74	0.79	-0.83	-0.51	0.97	-0.86	0.95	0.91	-0.43	0.64
Total Operating Expenses	0.96	0.63	0.97	0.92	1.0	-0.58	-0.74	0.67	-0.65	0.99		-0.75	-0.69	-0.79	-0.6	0.74	0.79	-0.8	-0.54	0.95	-0.85	0.95	0.88	-0.45	0.67
Income Before Tax	-0.85	-0.6	-0.66	-0.55	-0.76	0.72	0.99	-0.78	0.97	-0.79	-0.75		0.62	0.97	0.84	-0.44	-0.89	0.97	0.57	-0.88	0.9	-0.87	-0.85	0.4	-0.42
Total Other Income Expense Net	-0.73	-0.84	-0.64	-0.59	-0.68	0.76	0.6	-0.45	0.5	-0.67	-0.69	0.62		0.73	0.24	-0.63	-0.81	0.56	0.81	-0.68	0.8	-0.75	-0.58	0.75	-0.77
Net Income	-0.86	-0.76	-0.69	-0.59	-0.79	0.84	0.96	-0.67	0.92	-0.81	-0.79	0.97	0.73		0.69	-0.44	-0.97	0.91	0.75	-0.89	0.97	-0.92	-0.82	0.59	-0.61
Income Tax Expense	-0.71	-0.2	-0.59	-0.53	-0.61	0.25	0.8	-0.82	0.8	-0.65	-0.6	0.84	0.24	0.69		-0.39	-0.57	0.91	0.09	-0.71	0.59	-0.61	-0.76	-0.06	0.06
Discontinued Operations	0.68	0.4	0.8	0.8	0.74	-0.33	-0.45	0.61	-0.36	0.74	0.74	-0.44	-0.63	-0.44	-0.39		0.53	-0.55	-0.28	0.7	-0.58	0.61	0.74	-0.44	0.45
Minority Interest	0.83	0.87	0.7	0.62	0.79	-0.85	-0.9	0.55	-0.84	0.79	0.79	-0.89	-0.81	-0.97	-0.57	0.53		-0.85	-0.84	0.86	-0.99	0.91	0.78	-0.72	0.72
Tax Provision	-0.88	-0.54	-0.76	-0.68	-0.81	0.58	0.95	-0.83	0.92	-0.83	-0.8	0.97	0.56	0.91	0.91	-0.55	-0.85		0.45	-0.9	0.87	-0.85	-0.91	0.33	-0.33
Net Interest Income	-0.54	-0.95	-0.42	-0.35	-0.53	0.85	0.59	-0.1	0.53	-0.51	-0.54	0.57	0.81	0.75	0.09	-0.28	-0.84	0.45		-0.55	0.81	-0.7	-0.38	0.83	-0.87
Selling General Administrative	0.96	0.6	0.9	0.83	0.95	-0.7	-0.89	0.81	-0.82	0.97	0.95	-0.88	-0.68	-0.89	-0.71	0.7	0.86	-0.9	-0.55		-0.92	0.95	0.97	-0.51	0.6
Net Income From Continuing Ops	-0.88	-0.83	-0.77	-0.69	-0.85	0.85	0.91	-0.62	0.85	-0.86	-0.85	0.9	0.8	0.97	0.59	-0.58	-0.99	0.87	0.81	-0.92		-0.94	-0.84	0.71	-0.73
Reconciled Depreciation	0.95	0.72	0.86	0.76	0.95	-0.77	-0.87	0.65	-0.81	0.95	0.95	-0.87	-0.75	-0.92	-0.61	0.61	0.91	-0.85	-0.7	0.95	-0.94		0.85	-0.53	0.74
Selling And Marketing Expenses	0.91	0.47	0.87	0.82	0.89	-0.59	-0.85	0.89	-0.79	0.91	0.88	-0.85	-0.58	-0.82	-0.76	0.74	0.78	-0.91	-0.38	0.97	-0.84	0.85		-0.45	0.44
Non Recurring	-0.42	-0.81	-0.41	-0.38	-0.44	0.78	0.44	-0.16	0.37	-0.43	-0.45	0.4	0.75	0.59	-0.06	-0.44	-0.72	0.33	0.83	-0.51	0.71	-0.53	-0.45		-0.8
Non Operating Income Net Other	0.6	0.8	0.57	0.5	0.66	-0.81	-0.46	0.12	-0.38	0.64	0.67	-0.42	-0.77	-0.61	0.06	0.45	0.72	-0.33	-0.87	0.6	-0.73	0.74	0.44	-0.8

Click cells to compare fundamentals

Bioventus Account Relationship Matchups

Bioventus income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	31.0M	28.6M	38.7M	61.4M	57.4M	40.7M
Interest Expense	21.6M	9.8M	1.1M	25.8M	40.7M	42.7M
Total Revenue	340.1M	321.2M	430.9M	512.1M	512.3M	386.8M
Gross Profit	249.2M	233.5M	302.7M	331.1M	328.2M	267.5M
Other Operating Expenses	308.4M	299.4M	409.8M	560.7M	594.1M	390.2M
Operating Income	31.2M	21.2M	17.7M	(35.7M)	(81.7M)	(77.6M)
Ebit	31.2M	21.8M	13.1M	(170.6M)	(80.4M)	(76.4M)
Research Development	11.1M	11.2M	19.0M	25.9M	13.4M	15.1M
Ebitda	62.2M	50.4M	51.8M	(109.2M)	(23.1M)	(21.9M)
Cost Of Revenue	90.9M	87.6M	128.2M	181.0M	184.2M	119.3M
Total Operating Expenses	217.4M	211.7M	281.7M	379.7M	409.9M	270.9M
Income Before Tax	9.7M	15.9M	7.6M	(263.9M)	(121.1M)	(115.1M)
Total Other Income Expense Net	(21.5M)	(5.3M)	(2.6M)	(21.8M)	(39.4M)	(37.4M)
Net Income	6.9M	16.4M	9.6M	(213.4M)	(156.2M)	(148.4M)
Income Tax Expense	1.6M	1.2M	(2.0M)	(50.5M)	85K	89.3K
Tax Provision	1.6M	1.2M	(2.0M)	(50.5M)	(16.3M)	(17.1M)
Net Interest Income	(21.6M)	(9.8M)	(1.1M)	(25.8M)	(51.6M)	(49.0M)
Selling General Administrative	196.1M	190.3M	250.4M	327.4M	300.0M	266.9M
Net Income From Continuing Ops	8.1M	14.7M	9.6M	(213.4M)	(203.8M)	(193.6M)
Reconciled Depreciation	30.3M	28.6M	34.9M	66.8M	73.2M	48.2M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Bioventus Stock Analysis

When running Bioventus' price analysis, check to measure Bioventus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioventus is operating at the current time. Most of Bioventus' value examination focuses on studying past and present price action to predict the probability of Bioventus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bioventus' price. Additionally, you may evaluate how the addition of Bioventus to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Bioventus Historical Income Statement

About Bioventus Income Statement Analysis

Bioventus Income Statement Chart

Total Revenue

Gross Profit

Other Operating Expenses

Operating Income

Net Income Applicable To Common Shares

Bioventus income statement Correlations

Bioventus Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Bioventus income statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Bioventus Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cost Of Revenue	+ 1.0	Other Operating Expenses
Total Operating Expenses	+ 1.0	Other Operating Expenses
Gross Profit	+ 0.99	Total Revenue
Ebitda	+ 0.99	Ebit
Income Before Tax	+ 0.99	Ebit
Total Operating Expenses	+ 0.99	Cost Of Revenue

Net Income From Continuing Ops	- 0.99	Minority Interest
Minority Interest	- 0.97	Net Income
Net Interest Income	- 0.95	Interest Expense
Reconciled Depreciation	- 0.94	Net Income From Continuing Ops
Net Income From Continuing Ops	- 0.92	Selling General Administrative
Reconciled Depreciation	- 0.92	Net Income